Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2014, Vol. 41 Issue (5): 572-574    DOI: 10.12891/ceog16472014
Original Research Previous articles | Next articles
Serological prenatal screening and diagnosis for Down syndrome
Y. Duan1, Y. Li1, *(), Q. Xue1
1Department of Obstetrics and Gynecology, the Third Affiliated Hospital of Xinxiang Medical University, Xinxiang (China)
Download:  PDF(57KB)  ( 7 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: This study aimed to review and summarize the recent first-trimester and second-trimester prenatal screening and sequential prenatal screening to analyze the role of the existing prenatal screening system in the secondary prevention of birth defects. Materials and Methods: This study included 3,665 cases of 14~20-week pregnant women that underwent prenatal screening using double serum alphafetoprotein (AFP) and beta-human chorionic gonadotropin (β-hCG) and ultrasound screening; 512 cases of 9~12-week pregnant women underwent triple serological detection of serum β-hCG, pregnancy-associated plasma protein A (PAPP-A), and nuchal translucency (NT) for early screening. Results: The overall screening was with a high-risk rate of 8.52%. Among 356 cases of high-risk pregnant women, a total of 308 cases underwent karyotype analysis of fetal amniotic fluid cells. Of these, five cases of trisomy 21, one case of trisomy 18 and one case of “47, XXY” were diagnosed; among 37 cases of neural tube defect (NTD)-affected high-risk pregnant women, one case of anencephalus, and one case of open spina bifida were diagnosed. Conclusion: The overall detection rate for chromosome abnormalities was about 3.25% in the existing screening system, which could effectively prevent these seriously teratogenic fetuses from being born.
Key words:  Down syndrome      Prenatal screening      Prenatal diagnosis      Chromosome abnormality     
Published:  10 October 2014     
*Corresponding Author(s):  Y. LI     E-mail:  yujielicn@yeah.net

Cite this article: 

Y. Duan, Y. Li, Q. Xue. Serological prenatal screening and diagnosis for Down syndrome. Clinical and Experimental Obstetrics & Gynecology, 2014, 41(5): 572-574.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog16472014     OR     https://ceog.imrpress.com/EN/Y2014/V41/I5/572

[1] Kuntharee Traisrisilp, Supatra Sirichotiyakul, Fuanglada Tongprasert, Kasemsri Srisupundit, Suchaya Luewan, Phudit Jatavan, Sirinart Sirilert, Theera Tongsong. Increased nuchal translucency and fetal outcomes: a population-based study in Thailand[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 860-866.
[2] Thanakorn Heetchuay, Thotsapon Trakulmungkichkarn, Noel Pabalan, Nutthaphon Imsom-Somboon. Reference values of fetal atrioventricular time intervals derive from antegrade late diastolic arterial blood flow (ALDAF) from 14 to 40 weeks of gestation[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 867-874.
[3] Saša Raičević, Duško Kljakić, Filip Vukmirović, Miloš Z. Milosavljević. A giant placental chorioangioma with a resultant live birth; a discussion of management options[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 426-430.
[4] Suchaya Luewan, Pakorn Chaksuwat, Tip Pongsuvareeyakul, Theera Tongsong. Prenatal sonographic findings and management of placental mesenchymal dysplasia[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 439-443.
[5] Sureyya Saridas Demir, Erkan Cağliyan, Sabahattin Altunyurt. Retrospective analysis of pregnancy terminations and indications in a tertiary center[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 85-90.
[6] Y.J. Wu, C.J. Yu, W.H. Tian, Z. Xu. Prenatal diagnosis and molecular cytogenetic characterization of two hereditary chromosomal duplications with favorable outcomes[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 789-791.
[7] B.F. Zhou, C.X. Duan, D.L. Tang. Methylmalonic acidemia in prenatal diagnosis[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 617-619.
[8] D. Lu, D. Cao, Q. Zhao, X. Chen. Prenatal diagnosis and genetic counseling of mosaicism for chromosome t (7; 14) with a favorable outcome[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(3): 427-428.
[9] I. H. Kalelioglu, S. G. Erzincan, R. Has, A. Yuksel. Forehead and facial heights in Down syndrome and normal fetuses in the midtrimester of pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 220-227.
[10] W. B. Wang, Q. Wu, Y. Zhou, X. Zhong, Y. Ge, J. Zhang. A 10-year retrospective study on prenatal cytogenetic analyses[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 248-252.
[11] Q.C. Wu, W.B. Wang, L. Sun, Y.S. Xu, X.J. Xie, X.M. Ma, Z.Y. Su. Mutation analysis of the fibroblast growth factor receptor 3 gene in fetuses with thanatophoric dysplasia, type I[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(1): 7-11.
[12] G. Szabó, J. Rigó Jr.. Prenatal ultrasound diagnosis of abdominal pregnancy of ovarian origin[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 977-979.
[13] W. Homola, M. Zimmer. Safety of amniocentesis in normal pregnancies and pregnancies considered high-risk due to fetal genetic anomalies - an observational study[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(3): 403-407.
[14] D.Y. Ma, G. Liu, C.Y. Luo, A. Liu, J.J. Zhang, P. Hu, J. Cheng, Y.G. Wang, T. Jiang, J.F. Xu. A novel mutation in the mutations in the methyl-CpG-binding protein 2 (MECP2) gene in a Chinese patient with typical Rett syndrome and subsequent prenatal diagnosis[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(6): 924-929.
[15] S. G. Erzincan, N. C. Sayin, C. Inan, M. A. Yuce, F. G. Varol, S. Basaran. Cell-free DNA testing: is it reliable? A case report[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(6): 939-941.
No Suggested Reading articles found!